BR112014032964A2 - composto, composição farmacêutica, uso do composto, e, método para preparar o composto - Google Patents

composto, composição farmacêutica, uso do composto, e, método para preparar o composto

Info

Publication number
BR112014032964A2
BR112014032964A2 BR112014032964A BR112014032964A BR112014032964A2 BR 112014032964 A2 BR112014032964 A2 BR 112014032964A2 BR 112014032964 A BR112014032964 A BR 112014032964A BR 112014032964 A BR112014032964 A BR 112014032964A BR 112014032964 A2 BR112014032964 A2 BR 112014032964A2
Authority
BR
Brazil
Prior art keywords
compound
preparing
pharmaceutical composition
formula
âcompound
Prior art date
Application number
BR112014032964A
Other languages
English (en)
Inventor
Bai Hua
Zhong Jinqing
Liu Lifei
Zhu Qifeng
Zheng Xiaohe
Liu Xiaoyu
Zhao Xuyang
Gong Yongxiang
Original Assignee
Zhejiang Hisun Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49881293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014032964(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zhejiang Hisun Pharm Co Ltd filed Critical Zhejiang Hisun Pharm Co Ltd
Publication of BR112014032964A2 publication Critical patent/BR112014032964A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Abstract

1 / 1 resumo “composto, composiã‡ãƒo farmacãšutica, uso do composto, e, mã‰todo para preparar um composto” sã£o fornecidos na presente invenã§ã£o novos derivados de benzodioxol e seus mã©todos de preparaã§ã£o. estes compostos representados pela fã³rmula (i) ou seus sais farmaceuticamente aceitã¡veis tãªm atividade inibidora de acetilcolinesterase, de modo que podem ser usados no tratamento 1 2 ou na prevenã§ã£o de mal de alzheimer. as definiã§ãµes de r , r e a de fã³rmula (i) podem ser vistas na descriã§ã£o.
BR112014032964A 2012-07-03 2013-07-03 composto, composição farmacêutica, uso do composto, e, método para preparar o composto BR112014032964A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210226125.7A CN103524515B (zh) 2012-07-03 2012-07-03 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途
PCT/CN2013/000813 WO2014005421A1 (zh) 2012-07-03 2013-07-03 苯并间二氧杂环戊烯衍生物及其制备方法和用途

Publications (1)

Publication Number Publication Date
BR112014032964A2 true BR112014032964A2 (pt) 2017-06-27

Family

ID=49881293

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014032964A BR112014032964A2 (pt) 2012-07-03 2013-07-03 composto, composição farmacêutica, uso do composto, e, método para preparar o composto

Country Status (26)

Country Link
US (1) US9346818B2 (pt)
EP (1) EP2871184B1 (pt)
JP (1) JP6113275B2 (pt)
KR (1) KR101650776B1 (pt)
CN (2) CN103524515B (pt)
AU (1) AU2013286523B2 (pt)
BR (1) BR112014032964A2 (pt)
CA (1) CA2878000C (pt)
CL (1) CL2014003607A1 (pt)
DK (1) DK2871184T3 (pt)
EA (1) EA026210B1 (pt)
ES (1) ES2645643T3 (pt)
HK (1) HK1202857A1 (pt)
IL (1) IL236395A (pt)
IN (1) IN2014DN11112A (pt)
MX (1) MX357774B (pt)
MY (1) MY167075A (pt)
NO (1) NO2871184T3 (pt)
NZ (1) NZ703549A (pt)
PE (1) PE20150349A1 (pt)
PH (1) PH12015500012B1 (pt)
PT (1) PT2871184T (pt)
SG (1) SG11201500007WA (pt)
UA (1) UA113444C2 (pt)
WO (1) WO2014005421A1 (pt)
ZA (1) ZA201500692B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103524515B (zh) * 2012-07-03 2016-07-06 浙江海正药业股份有限公司 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途
CN105859732B (zh) * 2016-04-11 2018-04-06 浙江海正药业股份有限公司 制备ad‑35的工艺
KR20190008225A (ko) * 2016-05-13 2019-01-23 델노바 인코퍼레이티드 화학적 신경차단으로 인한 부작용의 치료
CN110812358B (zh) * 2018-08-10 2022-04-05 浙江海正药业股份有限公司 化合物ad-35在治疗与胃肠蠕动障碍相关疾病中的应用
CN113185447B (zh) * 2021-05-06 2023-07-21 四川大学 邻苯二甲酰半胱酰胺类化合物、其制备方法和用途
WO2023116915A1 (zh) * 2021-12-24 2023-06-29 珠海市藤栢医药有限公司 AChE/SERT双靶点抑制剂及其制备方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087541A (en) * 1975-03-06 1978-05-02 Boehringer Ingelheim Gmbh 2-(Aralkylaminoalkyl)phthalimidines
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JPH0610496B2 (ja) * 1987-09-17 1994-02-09 ダイハツ工業株式会社 車両用自動変速機のクラッチ構造
JP2777159B2 (ja) * 1988-12-22 1998-07-16 エーザイ株式会社 環状アミン誘導体を含有する医薬
IL125809A (en) 1998-08-17 2005-08-31 Finetech Lab Ltd Process and intermediates for production of donepezil and related compounds
RU2257384C2 (ru) 2000-02-29 2005-07-27 Мицубиси Фарма Корпорейшн Новые производные циклического амида
JPWO2003061658A1 (ja) * 2002-01-22 2005-05-19 エーザイ株式会社 インダノン誘導体を含有するシグマ受容体結合剤
AU2003247158A1 (en) 2003-07-01 2005-01-21 Hetero Drugs Limited Preparation of intermediates for acetyl cholinesterase inhibitors
WO2005076749A2 (en) 2004-02-11 2005-08-25 Jubilant Organosys Limited A novel process for the preparation of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine
AU2007203969B2 (en) 2006-01-04 2012-04-05 Cipla Limited Process and intermediate for preparation of donepezil
EP1976842B1 (en) 2006-01-18 2010-03-10 Siena Biotech S.p.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
US8247563B2 (en) * 2006-12-11 2012-08-21 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
CN103524515B (zh) * 2012-07-03 2016-07-06 浙江海正药业股份有限公司 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途

Also Published As

Publication number Publication date
CN103524515B (zh) 2016-07-06
EA026210B1 (ru) 2017-03-31
KR20150034224A (ko) 2015-04-02
AU2013286523A1 (en) 2015-02-05
MX357774B (es) 2018-07-24
UA113444C2 (xx) 2017-01-25
JP2015525740A (ja) 2015-09-07
US9346818B2 (en) 2016-05-24
CA2878000C (en) 2020-05-05
KR101650776B1 (ko) 2016-08-25
CN103524515A (zh) 2014-01-22
PH12015500012A1 (en) 2015-03-02
EP2871184B1 (en) 2017-09-06
EP2871184A1 (en) 2015-05-13
NZ703549A (en) 2015-11-27
MX2015000334A (es) 2015-04-14
CN104395303A (zh) 2015-03-04
NO2871184T3 (pt) 2018-02-03
CL2014003607A1 (es) 2015-03-13
PT2871184T (pt) 2017-11-14
WO2014005421A1 (zh) 2014-01-09
PE20150349A1 (es) 2015-02-28
US20150191480A1 (en) 2015-07-09
HK1202857A1 (en) 2015-10-09
DK2871184T3 (da) 2017-11-13
ZA201500692B (en) 2016-01-27
EA201590074A1 (ru) 2015-07-30
CN104395303B (zh) 2017-12-12
EP2871184A4 (en) 2015-12-23
IL236395A (en) 2017-01-31
CA2878000A1 (en) 2014-01-09
ES2645643T3 (es) 2017-12-07
AU2013286523B2 (en) 2017-06-22
IL236395A0 (en) 2015-02-26
SG11201500007WA (en) 2015-02-27
MY167075A (en) 2018-08-10
IN2014DN11112A (pt) 2015-09-25
PH12015500012B1 (en) 2015-03-02
JP6113275B2 (ja) 2017-04-12

Similar Documents

Publication Publication Date Title
BR112015014585A2 (pt) composto, composição farmacêutica, e, método de tratamento de um ser humano
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
BR112014032964A2 (pt) composto, composição farmacêutica, uso do composto, e, método para preparar o composto
ECSP14006132A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
BR112015014714A2 (pt) compostos carbamoilpiridona policíclicos e seu uso farmacêutico
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112016010080A8 (pt) compostos de pirazolopirimidina, composição farmacêutica e seu uso
CL2015001304A1 (es) Compuestos derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos.
BR112016006651B8 (pt) compostos derivados de quinolizina substituídos, composição farmacêutica que os compreende e uso dos referidos compostos
BR112014007257A2 (pt) composto, medicamento, métodos para inibir um colesterol 24-hidrolase em um mamífero e para a profilaxia ou tratamento de doença neurodegenerativa em um mamífero, e, uso do composto ou sal
BR112014025711A8 (pt) composto, medicamento, e, uso de um composto
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
CO6592102A2 (es) Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales
UA109792C2 (uk) Індоли як противірусні агенти відносно респіраторного синтиціального вірусу
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
BR112014031091A2 (pt) Derivados de piperidina para agonista de gpr119
DOP2015000169A (es) Compuestos tetracíclicos sustituidos con heterociclo y usos de los mismos para el tratamiento de enfermedades víricas
BRPI0906444B8 (pt) compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos
BR112013032391A2 (pt) antagonistas de trpv4
BR112013017362A2 (pt) composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores
BRPI1014802B8 (pt) profármacos de triptolida.
BR112014001083B8 (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto
BR112014029439A2 (pt) derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos
EA201600394A1 (ru) Трициклические соединения пиперидина

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements